CINPHA Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Cinclus Pharma Holding (STO: CINPHA)
›
Cinclus Pharma Holding (STO: CINPHA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 11.38 SEK on 19 November 2026, down 36.7% over 52 weeks. Its 52-week range is 10.60 SEK to 19.64 SEK: the price is 42.1% below the high and 7.4% above the low.
Its market capitalisation is 529.60M SEK.
Cinclus Pharma Holding reports return on equity of -49.8% and revenue down 80.8% year over year.
It holds more cash than debt, a net cash position of 224.28M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 45.00 SEK is 295.4% above the current price.